Michael R. McDevitt, PhD, ME

Michael R. McDevitt

Michael R. McDevitt is an Associate Attending Radiochemist in the Departments of Medicine and Radiology at Memorial Hospital and an Associate Laboratory Member in the Sloan Kettering Institute. He specializes in the development of targeted radiolabeled drug constructs. Radioimmunoconstructs are drugs that combine antibodies and radionuclides for therapeutic and imaging applications in the treatment of cancer. Recently, he has been investigating the integration of nanomaterials such as carbon nanotubes into his drug design paradigm. His research involves the investigation of new chemistry, radiochemistry, biological activity, pharmacokinetics, safety, stability, and the translation of novel drug construct candidates into the clinic.

After receiving his PhD degree in chemistry in 1985  from Case Western Reserve University, Dr. McDevitt worked in biotechnology and joined Memorial Sloan Kettering  in 1995. In 2004, he received a master’s degree in chemical engineering from The City University of New York. He is also a member of Memorial Sloan Kettering’s Brain Tumor Center and Nanotechnology Center.

Clinical Expertise

Radiolabeled Monoclonal Antibodies for use in Clinical Trials

Languages Spoken

PhD (Chemistry), Case Western Reserve University; ME (Chemical Engineering), The City College of New York

Publications by Michael R. McDevitt
Visit PubMed for full listing of Michael R. McDevitt journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.